Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Perou

Showing results (401-410 of 476) with videos related to

Pageof 48
Sort By:
Oncogene|September 24, 2013
c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancerR Nair, D L Roden, W S Teo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2016
A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of RelapseAleix Prat, Ana Lluch, Arran K Turnbull, et al.
Science Signaling|March 27, 2014
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancerJessica J Tao, Pau Castel, Nina Radosevic-Robin, et al.
Ebiomedicine|January 6, 2022
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancerAleix Prat, Valentina Guarneri, Tomás Pascual, et al.
Cancer Research|May 14, 2009
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristicsBryan T Hennessy, Ana-Maria Gonzalez-Angulo, Katherine Stemke-Hale, et al.
Nature Communications|February 16, 2026
Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)Tomás Pascual, Maria Vidal, Juan M Cejalvo, et al.
Cancer Research|March 3, 2017
Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast CancerJuan M Cejalvo, Eduardo Martínez de Dueñas, Patricia Galván, et al.
Nature|July 9, 2015
Progesterone receptor modulates ERα action in breast cancerHisham Mohammed, I Alasdair Russell, Rory Stark, et al.
The Journal of Clinical Investigation|June 24, 2020
FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic diseaseSusana Garcia-Recio, Aatish Thennavan, Michael P East, et al.
NPJ Breast Cancer|July 11, 2017
PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)Minetta C Liu, Brandelyn N Pitcher, Elaine R Mardis, et al.
Pageof 48

Showing results (401-410 of 476) with videos related to

Sort By:
Pageof 48
Oncogene|September 24, 2013
c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancerR Nair, D L Roden, W S Teo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2016
A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of RelapseAleix Prat, Ana Lluch, Arran K Turnbull, et al.
Science Signaling|March 27, 2014
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancerJessica J Tao, Pau Castel, Nina Radosevic-Robin, et al.
Ebiomedicine|January 6, 2022
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancerAleix Prat, Valentina Guarneri, Tomás Pascual, et al.
Cancer Research|May 14, 2009
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristicsBryan T Hennessy, Ana-Maria Gonzalez-Angulo, Katherine Stemke-Hale, et al.
Nature Communications|February 16, 2026
Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)Tomás Pascual, Maria Vidal, Juan M Cejalvo, et al.
Cancer Research|March 3, 2017
Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast CancerJuan M Cejalvo, Eduardo Martínez de Dueñas, Patricia Galván, et al.
Nature|July 9, 2015
Progesterone receptor modulates ERα action in breast cancerHisham Mohammed, I Alasdair Russell, Rory Stark, et al.
The Journal of Clinical Investigation|June 24, 2020
FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic diseaseSusana Garcia-Recio, Aatish Thennavan, Michael P East, et al.
NPJ Breast Cancer|July 11, 2017
PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)Minetta C Liu, Brandelyn N Pitcher, Elaine R Mardis, et al.
Pageof 48